Dina Ioffe, MD

Dina Ioffe, MD
This physician is not currently rated. Why?

Why is this doctor not rated?


To ensure the accuracy of our patient satisfaction scores, we require that providers who see patients receive a minimum number of completed patient-submitted surveys before their reviews are listed on their profiles. Star ratings on this site are collected on a rolling basis from the previous 12 months.
Additionally, some of the physicians listed on our site do not see patients directly, and therefore, do not receive evaluation and ratings from patients.

More about patient ratings

Assistant Professor, Division of Gastrointestinal Medical Oncology


  • Gastrointestinal Medical Oncology

Areas of Expertise

Colorectal Cancer, Neuroendocrine Tumors, Appendix Cancer, Liver, Gall Bladder & Bile Duct Cancer, Stomach (Gastric) Cancer, Esophageal Cancer, Pancreatic Cancer

Language(s) Other than English

  • Russian

Treatment Philosophy

My patients are my priority and my mission is to help them navigate a life-changing and overwhelming cancer diagnosis with compassion and support. I am committed to a holistic approach to patient care, considering my patients as unique individuals with different goals and wishes, rather than a person defined by their cancer. Central to this philosophy is the belief that effective cancer treatment should encompass the entire person, not just the tumor. As a gastrointestinal medical oncologist, I collaborate with surgical oncologists, radiation oncologists, gastroenterologists, interventional radiologists, pathologists, radiologists, and social workers to provide comprehensive yet personalized treatments that are not only medically effective but also consider a patient’s values, needs, preferences, lifestyle, and quality of life. 

This patient-centered, collaborative philosophy extends to my clinical and translational research. I aim to advance the field of gastrointestinal oncology, offer cutting edge treatments to my patients, expand our understanding of cancer biology, and ultimately improve patient outcomes. I am also dedicated to narrowing the gap in health disparities and inequities for vulnerable, underserved patient populations through personalized treatment and expanded access to high quality cancer care.

Clinical Locations

  • Fox Chase Cancer Center
    333 Cottman Avenue
    Philadelphia, PA 19111
    Phone: 888-369-2427
  • Fox Chase Cancer Center at Temple University Hospital
    3401 N. Broad Street
    Philadelphia, PA 19140
    Phone: 800-836-7536

Educational Background

  • MD, University of Maryland School of Medicine, Baltimore, MD, 2017 
  • BA, Washington University in Saint Louis, St. Louis, MO, 2009

Postgraduate Education and Training

  • Fellow & Chief Fellow, Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, 2023 
  • Resident, Internal Medicine, University of Maryland Medical Center, Baltimore, MD, 2020 


  • American Board of Internal Medicine - Internal Medicine
  • American Board of Internal Medicine - Medical Oncology


  • American Society of Clinical Oncology (ASCO) 
  • American Society of Hematology (ASH) 
  • American Medical Association (AMA) 
  • Associate, American College of Physicians (ACP)

Honors & Awards

  • Elena Gitelson Chief Fellow Award, 2023 
  • Clinician-Scientists Transdisciplinary Aging Research (Clin-STAR) Pilot Grant Award Recipient, 2023 
  • Fox Chase Cancer Center In Vino Vita Young Investigator Award, 2022 
  • ASCO Quality Training Program (QTP), Selected Participant, 2022 

Research Interests

Gastrointestinal Cancers, Hepatocellular Carcinoma, Geriatric Oncology, Translational Research, Quality Improvement, Health Disparities

Selected Publications


  1. Ioffe D, Dotan E. Evidence-Based Care of Older Adults With Metastatic Colorectal Cancer: Insights From Landmark Clinical Trials. J Clin Oncol. 2023 Oct 19:JCO2301337. doi: 10.1200/JCO.23.01337. Epub ahead of print. PMID: 37856768.  
  2. Ioffe D, McSweeny M, Hall MJ. Precision Medicine in the Era of Genetic Testing: Microsatellite Instability Evolved. Clin Colon Rectal Surg. 2023 July. doi: 10.1055/s-0043-1770385. 
  3. Dotan E, Catalano P, Lenchik L, Boutin R, Yao X, Marques HS, Ioffe D, Zhen DB, Li D, Wagner LI, Simon MA, Wong TZ, O'Dwyer PJ. The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer - defining a new treatment option for older vulnerable patients. J Geriatr Oncol. 2023 Apr;14(3):101474. doi: 10.1016/j.jgo.2023.101474. Epub 2023 Mar 22. PMID: 36963200. 
  4. Ioffe D, Dotan E. Guidance for Treating the Older Adults with Colorectal Cancer. Curr Treat Options Oncol. 2023 Jun;24(6):644-666. doi: 10.1007/s11864-023-01071-6. Epub 2023 Apr 13. PMID: 37052812. 
  5. Ioffe D, Phull P, Dotan E. Optimal Management of Patients with Advanced or Metastatic Cholangiocarcinoma: An Evidence-Based Review. Cancer Manag Res. 2021 Oct 27;13:8085-8098. doi: 10.2147/CMAR.S276104. PMID: 34737637; PMCID: PMC8558827. 
  6. Amr S, Ioffe D, Suzuki I, Mehra R, Cullen K, Goloubeva O. Treatment modalities, adverse events, and survival outcomes in older patients with head and neck squamous cell carcinoma. Head Neck. 2021 Dec;43(12):3935-3945. doi: 10.1002/hed.26893. Epub 2021 Oct 10. PMID: 34632677. 
  7. Lin J, Nichols E, Kesmodel SB, Ioffe D, Ioffe O, Tkaczuk KHR. Chapter 3: Phyllodes Tumor. In: Tkaczuk KHR (ed). Handbook of Breast Cancer and Related Breast Disease. Demos Medical Publishing, 1st Edition, 2016: 39-48.  

The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn more about our Patient Experience Ratings.

Ratings Breakdown

Loading ...

Patient comments

Loading ...